Role Of TRPV I Receptor In Bilateral Common Carotid Artery Occlusion (BCCAO) Induced Vascular Dementia In Rat.
Main Article Content
Abstract
Dementia is a devastating disorder that commonly affects people over the age of 65. Alzheimer’s disease and vascular dementia are the most common forms of dementias, A number of studies have implicated cardiovascular risks as important factors in the development of dementia. Loss of cognitive function and vascular risk factor produce pathological changes into the brain. Changes are Infarcts, Ischemia hypoperfusion, Hemoragic Brain and Atrophy (Degeneration of cells), Neurofibrillary tangles impairment. Bilateral Common Carotid Artery occlusion (BCCAO) has been considered as a critical cause for the development of cognitive decline and dementia of vascular origin.
In our study hypoperfusion reduced oxidative stress, nitric oxide level, Acetylcholine, SOD (Superoxide Dismutase). TRPV1 Receptors have been reported to be beneficial in improving memory deterioration.
Aim of this study is to explore the role of capsaicin in Bilateral Common Carotid Artery occlusion (BCCAO) induced vascular dementia .In clinical research capsaicin role is of antioxidant and other one shows anti-inflammatory actions. It showed significant cognitive deficits, cholinergic dysfunction (increased acetyl cholinesterase-AChE) activity along with increased brain oxidative stress (brain thiobarbituric acid reactive species), glutathione, as well as superoxide dismutase with an increase in malondialdehyde levels) and TTC (2,3,5 Triphenyltetrazolium chloride staining).
Furthermore, treatment of capsaicin reduced BCCAO induced learning and memory deficits.(Morris water maze-MWM), locomotion (Actophotometer), and limited cholinergic dysfunction, oxidative stress, and tissue damage, Estimation of Brain Total Protein, infarct volume suggesting that capsaicin TRPV1 Receptors may provide benefits in BCCAO induced VaD.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Matthews FE, Arthur A, Barnes LE, Bond J, Jagger C, Robinson L, Brayne C. on behalf of the Medical Research Council Cognitive Function and Ageing Collaboration. A two decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet. 2013 doi:10.1016/S01406736(13)615706. [PubMed] [Cross Ref]
World Health Organization. Dementia A Public Health Priority. World Health Organization; 2012.
Lezak,M.D.(1995). Neuropsychological Assessement (3ed.).New York: Oxford University Press.
American Psychiatric Association.(1994).Diagnostic and statistical manual of mental disorders (4 ed.).Washinton DC: American Psychiatric Association.
Zhao Y., Gu JH., Dai CL, et al. : Chronic cerebral hypoperfusion causes decrease of O GlcNAcylation, hyperphosphorylation of tau and behavioral deficits in mice. Front Aging Neurosci 2014;6:10.[PMC free article] [PubMed]
Bowler J. Modern concept of vascular cognitive impairment. Br Med Bull. 2007;83:291–305. [PubMed]
Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain. 2013;136:2697–2706. [PMC free article] [PubMed]
Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S (2011) Vascular Contributions to Cognitive Impairment and Dementia. Stroke 42:2672-2713.
Farkas E, Luiten PGM, Bari F (2007) Permanent, bilateral common carotid artery occlusion in the rat: A model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Research Reviews 54:162-180.
Breitner JC. Dementia-epidemiological considerations, nomenclature, and a tacit consensus definition. J Geriatr Psychiatry Neurol. 2006;19(3):129–36 (PubMed)
American Psychiatric Association, editor. DSM-5. Diagnostic and statistical manual of mental disorders. 5th ed. Washington/DC: American Psychiatric Publishing; 2013.(PubMed)
World Health Organization (WHO). International statistical classification of diseases and related health problems, vol. 10th revision Geneva: WHO; 2011.
Sorbi S., Hort J., Erkinjuntti T., Fladby T., Gainotti G., Gurvit H., et al. (2012). EFNS –ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur. J.Neurol. 19, 1159–117910.1111/j.14681331.2012.03784.x [PubMed] [Cross Ref]
Roman, G. and Royall, D. (2004). A diagnostic dilemma: Is “Alzheimer’s dementia” Alzheimer’s disease, vascular dementia, or both The Lancet Neurology, 3.
Sadowski, M., Pankiewicz, J., Scholtzova, H., Yong-sheng, L., Quartermain, D., Duff, K., and Wisniewski, T. (2004). Links between the pathology of alzheimer’s disease and vascular dementia. Neurochemical Resaerch, 29, 1257 – 1266.
Kalaria, R. (2002). Similarities between Alzheimer’s disease and vascular dementia. Journal of the Neurological Sciences, 203-204, 29-34.
Watari, K. and Gatz, M. (2002). Dementia: A cross-cultural perspective on risk factors. Generations. Diabetic Medicine, 18, 355-359.
Mehta, N., and Khan, I. (2002). Cardiology’s 10 greatest discoveries of the 20th century. Texas Heart Institute Journal, 29, 164-171.
Gorelick P. B., Scuteri A., Black S. E., Decarli C., Greenberg S. M., Iadecola C., et al. (2011). Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42, 2672–2713 10.1161/STR.0b013e3182299496 [PMC free article] [PubMed] [Cross Ref]
Hachinski V., Iadecola C., Petersen R. C., Breteler M. M., Nyenhuis D. L., Black S. E., et al. (2006).National Institute of Neurological Disorders and StrokeCanadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37, 2220–224110.1161/01.STR.0000237236.88823.47[PubMed] [Cross Ref]
Jellinger K. A. (2013). Challenges in the neuropathological diagnosis of dementias. Int. J.Neuropathol. 1, 8–52.
Jellinger K. A. (2007b). The enigma of mixed dementia. Alzheimers Dement. 3, 40–53 10.1016/j.jalz.2006.09.002 [PubMed] [Cross Ref]
Emilien, G rard, et al. Alzheimer Disease: Neuropsychology and Pharmacology. Basel: Birkhauser, 2004.
Xu Y, Zhang JJ, Xiong L, Zhang L, Sun D, Liu H. Green tea polyphenols inhibit cognitive impairment induced by chronic cerebral hypoperfusion via modulating oxidative stress. JNutr Biochem. 2010.
Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med.2004.
Kitamura A, Fujita Y, Oishi N, Kalaria RN, Washida K, Maki T, Okamoto Y, Hase Y,Yamada M, Takahashi J, Ito H, Tomimoto H, Fukuyama H, Takahashi R, Ihara M. Selective white matter abnormalities in a novel rat model of vascular dementia. Neurobiol Aging. 2012.
Choi JY, Morris JC, Hsu CY. (1998) Aging and cerebrovascular disease. Neurol Clin 16:687-711
Levy BI. (2001) Artery changes with aging: degeneration or adaptation? Dialogues in Cardiovascular Medicine 6:104 – 111
Pantoni L. (2002) Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 13:7-10
Baltan S, Besancon EF, Mbow B, Ye Z, Hamner MA, Ransom BR. (2008) White Matter Vulnerability to Ischemic Injury Increases with Age Because of Enhanced Excitotoxicity. J Neurosci 28:1479-1489
Gupta S, Sharma B. Pharmacological modulation of I(1)- imidazoline and 2 adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur J Pharmacol 2014a; 723:80-90.
Medina AE. Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front Neurosci 2011; 5: 21.
Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, WeinerMW, Shaw LM, Mattsson N, Blennow K et al (2020) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain J Neurol 138:3373–3385 Abstract/FREE Full Text Google Scholar
Galisova A, Baciak L, Jozefovicova M, et al. Pathophysiological rat model of vascular dementia: magnetic resonance spectroscopy, microimaging and behavioral study. Brain Res 2014; 1568: 10-20.
Du J, Ma M, Zhao Q, et al. Mitochondrial bioenergetic deficits in the hippocampi of rats with chronic ischemia-induced vascular dementia. Neurosci 2013; 231: 345-52.
Sharma B, Singh N. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction invascular dementia during experimental diabetes. Curr Neurovasc Res 2010; 7(3): 180-91.
Gupta S, Sharma B. Pharmacological modulation of I(1)-imidazoline and alpha2-adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur J Pharmacol 2014a; 723:80-90.
Sakr HF, Khalil KI, Hussein AM, Zaki MS, Eid RA, Alkhateeb M.Effect of dehydroepiandrosterone (DHEA) on memory and brain derived neurotrophic factor (BDNF) in a rat model of vascular dementia. J Physiol Pharmacol 2014; 65(1): 41-53.
Xi Y, Wang M, Zhang W, et al. Neuronal damage, central cholinergic dysfunction and oxidative damage correlate with cognitive deficits in rats with chronic cerebral hypoperfusion. Neurobiol Learn Mem 2014; 109: 7-19.
Chen Y, Mancuso J, Zhao Z, et al. Vasodilation by in vivo activation of astrocyte endfeet via two-photon calcium uncaging as a strategy to prevent brain ischemia. J Biomed Opt 2013; 18(12):126012.
Fotuhi M, Hachinski V, Whitehouse PJ. Changing perspectives regarding late-life dementia. Nat Rev Neurol. 2009;5:649–58.
de La Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3:184–90.
Chui H. Vascular dementia, a new beginning: shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin. 2000;18:951-978.
Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA (2011). Microinfarct pathology, dementia, and cognitive systems. Stroke doi:10.1161/STROKEAHA.110.595082 PubMedPubMedCentral
Bink DI, Ritz K, Aronica E, van deer Weerd L, Daemen MJ (2013) Mouse models to study the effect of cardiovascular risk factors on brain structure and cognition. J Cereb Blood Flow Metab. doi:10.1038/jcbfm.2013.140PubMedPubMedCentral.
Isingrini, E., Camus, V., le Guisquet, A. M., Pingaud, M., Devers, S., & Belzung, C. (2010). Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: A model of fluoxetine resistance in mice. PLoS ONE, 5(4). https://doi.org/10.1371/journal.pone.0010404
16. Jollow D.J., G. J. R. (1974). Bromobenzene-induced Liver Necrosis. Protective role of Glutathione and Evidence for 3,4-Bromobenzene oxide as the hepatotoxic metabolite. Pharmacology.
17. Köhler, O., E. Benros, M., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014). Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. In JAMA Psychiatry (Vol. 71, Issue 12, pp. 1381–1391). American Medical Association. https://doi.org/10.1001/jamapsychiatry.2014.1611
18. Kolla, N., Wei, Z., Richardson, J. S., & Li, X. M. (2005). Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. Journal of Psychiatry and Neuroscience, 30(3), 196–201.
19. Mandal S, Jaiswal V, Sagar MK, Kumar S. Formulation and evaluation of carica papaya nanoemulsion for treatment of dengue and thrombocytopenia. Plant Arch. 2021;21:1345-54.